title: [Who protects physicians and patients from                     guidelines?].
authors: Karls-Universität Heidelberg, Maybachstr. 14, 68169 Mannheim. christine.schummer@medma.uni-heidelberg.de
authors: M
authors: M
authors: Wehling
mesh_terms: D000241:Adenosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000368:Aged; D000638:Amiodarone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D003245:Consensus Statements as Topic; D000077764:Dronedarone; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D057239:Early Termination of Clinical Trials / Q000331:legislation & jurisprudence; D019317:Evidence-Based Medicine / Q000331:legislation & jurisprudence; D005858:Germany; D019983:Guideline Adherence / Q000331:legislation & jurisprudence*; D006331:Heart Diseases / Q000188:drug therapy*; D006801:Humans; D008318:Malpractice / Q000331:legislation & jurisprudence*; D009313:National Health Programs / Q000331:legislation & jurisprudence*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D058921:Purinergic P2Y Receptor Antagonists / Q000009:adverse effects* / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012307:Risk Factors; D000077486:Ticagrelor
chemical_list: D000889:Anti-Arrhythmia Agents; D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D000077486:Ticagrelor; D000077764:Dronedarone; D000241:Adenosine; D000638:Amiodarone